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ABSTRACT 
Glucose is the most common substrate for energy metabolism.  Despite the varying demands 
for glucose, the body needs to regulate its internal environment and maintain a constant and 
stable condition. Glucose homeostasis requires harmonized interaction between several 
tissues, achieving equilibrium between glucose output and uptake. In this thesis we aimed to 
investigate factors modulating glucose homeostasis in a rat model of type 2 diabetes, the 
Goto-Kakizaki (GK) rat. In addition, we investigated sex differences in hepatic carbohydrate 
and lipid metabolism in healthy rats. 
In Paper I, three-week but not three-day treatment with a Southeast Asian herb, 
Gynostemma pentaphyllum (GP), significantly reduced plasma glucose (PG) levels in GK 
rats. An intra-peritoneal glucose tolerance test (IPGTT) was significantly improved in GP-
treated compared to placebo-treated group. In the GP treated rats, the glucose response in an 
intra-peritoneal pyruvate tolerance test was significantly lower, indicating decreased 
gluconeogenesis, and hepatic glucose output (HGO) was reduced. GP-treatment significantly 
reduced hepatic glycogen content, but not glycogen synthase activity. The study provides 
evidence that the GP extract exerted anti-diabetic effect in GK rats, reducing PG levels and 
HGO, suggesting that GP improves the hepatic insulin sensitivity by suppressing 
gluconeogenesis. 
In Paper II, shikonin, a naphthoquinone derived from the Chinese plant Lithospermum 
erythrorhizon, increased glucose uptake in L6 myotubes, but did not phosphorylate Akt. 
Furthermore we found no evidence for the involvement of AMP activated protein kinase 
(AMPK) in shikonin induced glucose uptake. Shikonin increased the intracellular levels of 
calcium in these cells and stimulated the translocation of GLUT4 from intracellular vesicles 
to the cell surface in L6 myotubes. In GK rats treated with shikonin once daily for 4 days, PG 
levels were significantly decreased. In an insulin sensitivity test, the absolute PG levels were 
significantly lower in the shikonin-treated rats. These findings suggest that shikonin increases 
glucose uptake in muscle cells via an insulin-independent pathway dependent on calcium.  
In Paper III, GK and control Wistar rats were injected daily for up to 4 weeks with either a 
non-hematopoietic erythropoietin analog ARA290 or with placebo. PG levels in GK but not 
Wistar rats were significantly lower in ARA290-treated compared to placebo. After 2 and 4 
weeks, the IPGTT was significantly improved in ARA290 treated GK rats. In insulin and 
pyruvate tolerance tests, glucose responses were similar in ARA290 and placebo groups. In 
isolated GK rat islets, glucose-stimulated insulin release was two-fold higher and islet 
intracellular calcium concentrations in response to several secretagogues were significantly 
higher in ARA290-treated than in placebo-treated GK rats. These findings indicate that 
treatment with ARA290 significantly improved glucose tolerance in diabetic GK rats, most 
likely due to improvement of insulin release.  
In Paper IV, sex differences in hepatic carbohydrate and lipid metabolism were 
characterized in healthy rats. No sex-differences were observed regarding hepatic triglyceride 
content, fatty acid oxidation rates or insulin sensitivity. Male rats had higher ratios of insulin 
to glucagon levels, increased hepatic glycogen content, a lower degree of AMPK 
phosphorylation, a higher rate of glucose production and higher expression levels of 
gluconeogenic genes, as compared to female rats. A sex-dependent response to mild 
starvation was observed with males being more sensitive. In conclusion, sex-differences 
reflect a higher capacity of the healthy male rat liver to respond to increased energy demands. 
 
Key words: glucose homeostasis, type 2 diabetes, GK rats, L6 myotubes, hepatic glucose 
output, insulin sensitivity, sex differences. 
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1 BACKGROUND 
 
1.1 GLUCOSE HOMEOSTASIS 
1.1.1 Physiology of plasma glucose concentration 
Glucose is the most common substrate for energy metabolism. Certainly, under normal 
circumstances glucose is the only form of energy that can be used by the brain and 
central nervous system (Thorens and Mueckler, 2010, Pellerin and Magistretti, 2003). 
The amount of glucose in the circulation is dependent upon a balance of the rate of 
glucose entering the circulation (glucose appearance) and the rate of glucose removal 
from the circulation (glucose disappearance) (Gerich, 2000).  Circulating plasma 
glucose is derived from intestinal absorption, glycogenolysis, the breakdown of 
glycogen, which is the storage form of glucose, and gluconeogenesis, the formation of 
glucose primarily from lactate, glycerol and amino acids during the fasting state (Saltiel 
and Kahn, 2001). Despite the varying levels of glucose after a meal or during fasting 
and exercise, the body needs to regulate its internal environment and maintain a 
constant and stable condition (Vidal-Puig and O'Rahilly, 2001). Hence, blood glucose 
levels are under the regulation of various homeostatic control mechanisms which 
maintain them within a narrow range in both the fasting and feeding states. 
 
The glucoregulatory hormones in glucose homeostasis require a harmonized interaction 
between several tissues, achieving equilibrium between glucose output and uptake.  
Insulin is the major regulator of glucose metabolism, although its actions are modified 
in many respects by counter-regulatory hormones (glucagon, adrenaline, cortisol and 
growth hormone). 
 
To maintain circulating glucose concentrations in a relatively narrow range, insulin 
decreases blood glucose levels by suppressing hepatic glucose output and facilitating 
glucose uptake in liver and extrahepatic tissues (muscle and adipose tissue) (Thorens 
and Mueckler, 2010, Pessin and Saltiel, 2000). This regulation depends on the state of 
the body and can be modified by counter-regulatory hormones, which increase blood 
glucose concentrations. The effect of counter-regulatory hormones is to cause greater 
production of glucose from the liver and less utilization of glucose in adipose and 
muscle tissues. During fasting, the liver produces glucose both by glycogenolysis and 
gluconeogenesis, whereas in the fed state the liver takes up glucose and stores glucose 
as glycogen. Skeletal muscle, due to its large mass, is the principal organ for glucose 
disposal in the body (DeFronzo et al., 1985).  
 
1.1.2 Insulin 
Insulin is a hormone that is essential for regulating energy storage and glucose 
metabolism in the body (Pessin and Saltiel, 2000). Insulin stimulates liver, muscle, and 
adipose tissues and other insulin-sensitive cells to take up glucose from blood to be 
stored as glycogen in liver and muscle. 
 
Insulin is secreted by the pancreatic β-cells in response to elevated levels of nutrients, 
such as increased circulating levels of glucose and amino acids after a meal. In liver, 
insulin decreases glycogenolysis and gluconeogenesis, thereby reducing hepatic 
glucose production (Sesti, 2006). In skeletal muscle and adipose tissue mainly insulin 
increases the rate of glucose uptake (DeFronzo and Tripathy, 2009, Roy et al., 1998).  
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The insulin receptor  is composed of two extracellular α-subunits and two 
transmembrane β-subunits linked together by disulfide bonds to form an α2β2 complex 
(Kahn and White, 1988, Yarden and Ullrich, 1988, Sesti et al., 2001, Van Obberghen, 
1994). Binding of insulin to the α-subunits induces a signal across the plasma 
membrane that leads to conformational change of the receptor, resulting in 
autophosphorylation of several tyrosine residues within the β-subunits. The receptor 
then undergoes a series of intramolecular transphosphorylations. 
 
The activated insulin receptor phosphorylates several substrates on tyrosine residues, 
including members of the insulin receptor substrate family (IRS1/2/3/4) (White, 1997, 
Patti and Kahn, 1998, Sesti et al., 2001). This further triggers phosphorylation of 
phosphatidylinositol 3-kinase (PI3K). The activation of PI3K leads to activation of Akt 
(also known as protein kinase B, PKB) at different sites (serine/ threonine) (Van 
Obberghen et al., 2001, Krook et al., 1997). Akt activation leads to translocation of 
insulin-responsive glucose transporter 4 (GLUT4) vesicles from their intracellular pool 
to the plasma membrane, and consequently increased glucose uptake into cells (Lanner 
et al., 2008). 
  
1.1.2.1 Insulin resistance (IR) 
IR is a condition in which the cells of the body become resistant to the effects of 
insulin, causing physiological insulin levels to be insufficient to regulate glucose 
homeostasis by peripheral target tissues (Petersen and Shulman, 2002). As a result, a 
higher amount of insulin than normal is needed to achieve a sufficient insulin response. 
IR has been associated with conditions such as cardiovascular disease (CVD), 
hypertension, type 2 diabetes (T2D), obesity, and nonalcoholic fatty liver disease (Cohn 
et al., 2005). 
IR in classic insulin target tissues (e.g, liver, skeletal muscle and adipose tissue) results 
in perturbation of body glucose homeostasis. IR in liver leads to reduced glycogen 
synthesis and storage and a failure to suppress glucose output into the blood (Kim et al., 
2008). In extra-hepatic tissues, IR reduces glucose uptake and the storage of glucose as 
glycogen and triglycerides, respectively (Petersen and Shulman, 2002).  
Initially β-cells compensate for IR by producing additional amounts of insulin, so that 
normal glucose tolerance is maintained (Purrello and Rabuazzo, 2000). This results in a 
state of hyperinsulinemia. Despite elevated insulin levels, as IR worsens, increased 
insulin secretion from the β-cells becomes less effective at lowering plasma glucose 
levels. Eventually, the secretion of insulin reaches a point at which it is unable to 
counteract the IR level, and subsequently hyperglycemia develops (Petersen and 
Shulman, 2002). 
 
1.1.2.2 Insulin secretion  
Insulin is synthesized in β-cells and stored in the cytosol in secretory granules. A rise in 
plasma glucose is the most important stimulus for insulin secretion. Glucose is 
transported into the β-cells by facilitated diffusion through the glucose transporter -2 
(GLUT2) (Fig. 1). Glucose is metabolized, with subsequent production of ATP. An 
increase in cytoplasmic ATP/ADP ratio leads to the closure of ATP-sensitive potassium 
channels, causing depolarization of the plasma membrane. This in turn leads to the 
opening of voltage-gated calcium channels and an influx of extracellular calcium into 
the cell. An increase of cytoplasmic levels of Ca2+ causes vesicles containing insulin to 
be released from the β-cells by exocytosis (Ashcroft et al., 1994). 
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Fig. 1: Schematic model of the glucose induced insulin secretion in pancreatic β-cells. 
 
 
 
 
1.1.3 Glucose transporters  
Glucose cannot diffuse directly into cells, but enters by one of two glucose transporter 
mechanisms, Na+-dependent-glucose transporters (SGLTs) and Na+-independent 
glucose transporters (GLUTs). GLUTs are widely distributed in nearly all cells. 
GLUT1 is found in the brain and erythrocytes, GLUT2 is primarily in pancreatic β-
cells, the liver and the kidneys, GLUT3 in the brain, and GLUT4 is found in heart, 
skeletal muscle and adipose tissue (Thorens and Mueckler, 2010). GLUTs exist in cell 
membranes in two conformational states. Glucose binding to the extracellular form 
alters its conformation and permits transport of glucose across the cell membrane. 
Glucose movement then follows a concentration gradient from high to low 
concentrations, so-called facilitated diffusion. 
 
1.1.4 Liver in glucose homeostasis 
The liver is a unique organ in keeping the balance between glucose release and uptake.  
In the fasted state, the liver is the primary producer of endogenous glucose , whereas in 
the fed state,  elevations in circulating glucose and insulin  stimulate the liver to take up 
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and store glucose (Edgerton et al., 2009). Therefore, the liver plays an essential role in 
maintaining glucose homeostasis.  
Glucose is produced in the liver through two processes: glycogenolysis, from glycogen 
stores, and gluconeogenesis (Edgerton et al., 2009). In the fasting state, endogenous 
glucose production is necessary to keep the plasma glucose levels constant. The liver is 
responsible for about 80% of endogenous glucose production to the circulation in the 
fasting state (Cano, 2002, Bischof et al., 2001). Glycogenolysis and gluconeogenesis 
are partly under the control of glucagon. Glycogenolysis produces glucose during the 
first 8–12 hours of fasting. Over longer period of fasting, when glycogen in the liver is 
depleted, the liver switches to gluconeogenesis to maintain glucose levels.  
 
In the fed state, insulin suppresses hepatic glucose production directly by its interaction 
with its hepatic receptors promoting glycogen synthesis by stimulating glycogen 
synthase and inhibiting glycogen phosphorylase (Edgerton et al., 2009). 
 
In addition, insulin suppresses the release of gluconeogenic substrates from 
extrasplanchnic tissues and inhibits glucagon secretion from pancreatic α-cells, leading 
to cessation of glucose production via glycogenolysis and gluconeogenesis 
(Cherrington et al., 2007, Ballian and Brunicardi, 2007, Ader and Bergman, 1990, 
Giacca et al., 1992). Thus during both fasting and feeding, decreased hepatic insulin 
sensitivity results in dysregulation of hepatic glucose metabolism with impairments in 
fasting glucose levels and glucose tolerance such as in T2D. 
 
Hepatic IR is accompanied by elevated basal hepatic glucose production that leads to 
fasting hyperglycemia (Consoli, 1992, Radziuk and Pye, 2002). On the other hand, in 
postprandial state hepatic IR leads to diminished suppression of hepatic glucose 
production and  glucose clearance which further contribute to impaired glucose 
tolerance and postprandial hyperglycemia (Wahren and Ekberg, 2007). The rate at 
which the liver produces glucose during fasting, and the degree to which it takes up 
glucose following a meal, are determinants of glucose homeostasis. Thus, 
hyperglycemia associated with impairments in the regulation of fasting glucose 
production and glucose tolerance may be improved by therapeutics which target IR in 
the liver (Edgerton et al., 2009). 
 
1.1.5 Skeletal muscle in glucose hemostasis 
Skeletal muscle, due to its large mass (Shearer and Graham, 2002, Ehrenborg and 
Krook, 2009) is the primary site for glucose disposal in the body, such that up to 75% 
of  a glucose load  is converted to glycogen (Saltiel and Kahn, 2001, Jue et al., 1989). 
Glucose uptake into skeletal muscle provides cells with an important energy substrate 
and has a major impact on body glucose homeostasis.  
 
The muscle uses energy to drive all the processes in order for the muscle to contract. 
Glucose and lipids are the main oxidative fuel substrate in muscle (Frayn, 2003). 
At rest, glucose is the main energy substrate for skeletal muscle in the fed state. Storage 
of glucose as glycogen is enhanced by insulin stimulation of glucose uptake in muscle, 
via the increased the translocation of intracellular vesicles containing GLUT4 to the 
cell surface (Tremblay et al., 2003, Jessen and Goodyear, 2005, Ryder et al., 2001).  
Under fasting conditions, plasma glucose and insulin concentrations are low, leading to 
an increase in non-esterified fatty acid (NEFA) concentrations; thus fatty acids (FA) are 
then the main energy substrate for skeletal muscle. During exercise or muscle 
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contraction, glucose uptake increases, as a result of activation of AMP-activated protein 
kinase (AMPK) as well as increased intracellular Ca2+ levels (Hutchinson et al., 2008). 
The latter is also able to stimulate glucose uptake independently of contraction (Youn 
et al., 1991). 
Skeletal muscle is also a primary site of IR in the context of metabolic disease, in 
particular, T2D and obesity (Bouzakri et al., 2005). 
 
1.2 TYPE 2 DIABETES  
T2D is a common disease involving multiple organs with dysregulation in glucose and 
lipid metabolism. It is a heterogeneous disorder characterized by chronic 
hyperglycemia due to impaired insulin secretion and insulin sensitivity. Noticeably, 
either IR or impaired β-cell function alone will not lead to the development of T2D 
(Ostenson, 2001). Rather, to develop T2D both IR and impaired β-cell should exist (Fig 
2). 
The incidence of diabetes is rapidly increasing worldwide and is estimated to be 285 
million in 2010, and will exceed 400 million in 2030 (Shaw et al., 2010). Of these 
patients, almost 90% are accounted for by T2D (Nolan et al., 2006). 
Available treatments for T2D moderate the glycemia, but fail to completely normalize 
metabolism. The long-standing elevation of plasma glucose as well as dyslipidemia is 
associated with chronic diabetes complications. Currently available therapies for T2D 
include sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, 
glucagon-like peptide-1 (GLP-1) analogues, dipeptidyl peptidase-IV (DPP-IV) 
inhibitors and insulin. Patients treated with monotherapy often progress to combination 
therapy to obtain better control, and many patients eventually require insulin therapy 
(DeFronzo, 1999).   
Sulfonylureas (SUs) increase insulin secretion by closing the potassium channels in β-
cell membranes, leading to membrane depolarization, opening of voltage-dependent 
calcium channels and finally exocytosis of insulin. In addition to the side effects of 
SUs, which includeincreasedweight and a risk for hypoglycaemia, many patients 
develop secondary failure to SU action after 5-10 years. Non-SU insulin secretagogues, 
such as meglitinides (repaglinide and nateglinide) act via a mechanism similar to SU 
but possess shorter therapeutic duration.  Biguanides (metformin) inhibit 
gluconeogenesis, and may also enhance extrahepatic glucose uptake via stimulation of 
AMP kinase (Wiernsperger and Bailey, 1999). α-Glucosidase inhibitors decrease 
glucose uptake from the intestine by inhibiting the degradation of polysaccharides to 
monosaccharides . 
Thiazolidinediones (TZDs) act as agonists for the peroxisome proliferator activated 
receptor (PPAR) γ, and increase peripheral glucose uptake. Moreover, GLP-1 
analogues (i.e. exenatide and liraglutide), and also DPPIV inhibitors ( i.e. sitagliptin 
and vildagliptin) exert several effects, such as glucose-dependent stimulation of insulin 
release, suppression of glucagon release, slowdown of gastric emptying and reduction 
of food intake  (Nauck, 1998, Perfetti and Merkel, 2000). 
The number of therapies available for the treatment of T2D has increased. However, 
there are still difficulties in reaching the goal of normalizing glycemia without side 
effects. Hence, there is a great medical need to develop novel drugs that are both 
effective and which are free of side effects. 
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Fig. 2: Impairment of insulin secretion and insulin sensitivity in T2D. 
                       
1.2.1 Novel factor modulating glucose homeostasis  
1.2.1.1 Gynostemma pentaphyllum (GP)   
Gynostemma pentaphyllum (GP) Makino-Cucurbitaceae is a medicinal herb that has 
been widely used in Vietnamese and some other Asian countries;it has also been 
advertised in some European countries as a herbal tea. GP extract reportedly has 
numerous benefits, such as cholesterol-lowering, immune-potentiating, anti-tumor, 
anti-oxidant, and anti-diabetic effects (Li et al., 1993, Lin et al., 1993, Zhou et al., 1998, 
Jang et al., 2001). 
 
An extract of GP has been shown to decrease plasma glucose levels in mice and rats. 
From GP extract we purified and characterized an active substance, phanoside, that was 
demonstrated to stimulate insulin secretion in islets from healthy and diabetic rats and 
rats in vivo (Norberg et al., 2004, Hoa et al., 2007). Moreover, in a randomized 
placebo-controlledclinical trial in drug-naïve patients with T2D, GP extract 
significantly improved HbA1c values and fasting plasma glucose levels (Huyen et al., 
2010). In addition, Homeostasis Model of Assessment –Insulin Resistance (HOMA-IR) 
studies indicated that the main effect was accomplished by improved insulin sensitivity. 
 
1.2.1.2 Shikonin 
Shikonin is a substance that is extracted from the dried gromwell root of the Chinese 
plant Lithospermum erythrorhizon (LE) (Fig 3). LE has been used in traditional 
Chinese medicine to treat a variety of disorders. As its genitor plant, shikonin was 
reported to possess numerous pharmacological properties, including anti-inflammatory 
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and antitumor properties and the ability to promote wound healing activity (Chen et al., 
2002, Long et al., 2011). Shikonin has also been shown to increase glucose uptake in 
adipose tissues by augmenting insulin signaling (Kamei et al., 2002).  
 
Fig.3 
Chemical structure of shikonin (C16H16O5; molecular weight, 288.3 (Chen et al., 
2003). 
.   
   
1.2.1.3 ARA290 (Erythropoietin analogue) 
ARA290 is a non-hematopoietic erythropoietin (EPO), analogue that consists of 11 
amino acids. EPO is a well-established stimulant of red blood cell formation and 
survival, has been shown to exert tissue protective effects (anti-inflammatory and anti-
apoptotic) (Choi et al., 2010). Erythropoietin receptor (EPO-R) is present in erythroid 
cells as well as in other non-erythroid tissues, including pancreatic islets (Fenjves et al., 
2003). EPO treatment was shown to protect against diabetes development in type 1 and 
type 2 diabetic animal models by effects within the islets (Choi et al., 2010). However 
treatment with EPO is associated with an increased hematocrit that lead to an increased 
risk for the development of thrombosis. The EPO analogue, ARA290 (Brines et al., 
2008), which lacks such a hematopoietic action, binds to the EPO-R –β-common 
receptor and protects a number of tissues in response to injury.  
 
1.3 GOTO-KAKIZAKI (GK) RATS  
The Goto-Kakizaki (GK) rat is a model of hereditary type 2 diabetes developed by 
repeated selective breeding of normal Wistar (W) rats, based on selecting male and 
female W rats with the highest glucose levels within the normal range during a glucose 
tolerance test (Goto et al., 1976, Yagihashi et al., 1978). Repetition of the selective 
breeding over numerous generations resulted in the production of non-obese diabetic 
rats from W rats, named Goto-Kakizaki rats. Colonies in Paris, Stockholm, Seattle and 
other sites were then initiated with breeding pairs from Japan (Metz et al., 1999, Lewis 
et al., 1996, Portha et al., 1991, Ostenson et al., 1993c). The Stockholm rat colony was 
initiated from progenitors delivered from the F40 generation of the original colony. 
The GK rat develops hyperglycemia post-natally and maintains moderately enhanced 
plasma glucose levels during its lifetime. In common with in human T2D, glucose 
intolerance in the GK rat is due partly to impaired insulin secretion, but also to IR in 
target tissues. 
 
In these animals, impaired insulin release appears in early life and seems to be the 
primary defect (Abdel-Halim et al., 1995, Miralles and Portha, 2001). IR in skeletal 
muscle and liver is moderate and is most likely secondary to hyperglycemia, at least in 
case of the muscle (Bisbis et al., 1993, Abdel-Halim et al., 1995, Krook et al., 1997) . 
In GK rats, impaired glucose stimulated insulin secretion has been demonstrated in vivo 
(Gauguier et al., 1996, Salehi et al., 1999, Portha et al., 1991), in isolated pancreatic 
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islets (Hughes et al., 1994, Ostenson et al., 1993b), and in the perfused isolated 
pancreas (Abdel-Halim et al., 1996, Portha et al., 1991, Ostenson et al., 1993b). In GK 
rats from our colony, pancreatic insulin content and β-cells density are normal (Portha 
et al., 1991, Abdel-Halim et al., 1995, Abdel-Halim et al., 1994). The defective insulin 
response to glucose in GK rats is  accompanied by a number of abnormalities in islet 
glucose metabolism, e.g. increased glucose cycling and increased glucose utilization 
(Hughes et al., 1994, Giroix et al., 1993, Sener et al., 1993, Ostenson et al., 1993b), 
decreased FAD-linked glycerol phosphate dehydrogenase and pyruvate carboxylase 
activities (MacDonald et al., 1996, Ostenson et al., 1993a) and decreased pyruvate 
dehydrogenase activity (Zhou et al., 1995). 
 
GLUT2 is found to be underexpressed, but not to the degree that could account for the 
impairment of insulin release (Ohneda et al., 1993). This hypothesis is supported by the 
fact that glucokinase/hexokinase activities were found to be normal (Tsuura et al., 
1993, Ostenson et al., 1993a). In addition, glycolysis rates in GK rat islets are 
unchanged or increased compared with control Wistar rat islets (Hughes et al., 1994, 
Ling et al., 1998, Giroix et al., 1993). Moreover, oxidation of glucose has been reported 
to be unchanged (Hughes et al., 1994, Sener et al., 1993, Ostenson et al., 1993b) . 
In GK rats, hepatic IR is evident by an increase in hepatic glucose output (HGO) in 
connection with a dysregulation of hepatic fructose-2-6-bisphosphate. This hepatic IR 
is characterized by decrease in insulin receptor number but normal tyrosine kinase 
activity (Bisbis et al., 1993). 
 
In the skeletal muscle, a defective activation of glucose accumulation into glycogen, 
possibly due to chronic activation of protein kinase C (Villar-Palasi and Farese, 1994, 
Avignon et al., 1996) has been suggested to contribute to IR and hyperglycemia in GK 
rats. Additionally, defective post-receptor signaling was characterized by alterations in 
insulin-stimulated glucose transport and PI-3K-activated Akt kinase (Krook et al., 
1997). 
 
The GK rat is regarded as one of the most relevant rodent models of non-obese T2D 
and has been widely used in experimental diabetes research. In this thesis (Papers I, II 
and III), GK rats were used to observe and investigate factors modulating glucose 
homeostasis. The GK rats used were bred at this department (Department of Molecular 
Medicine and Surgery (Karolinska Institute, Stockholm, Sweden) 
 
1.4 SEX DIFFERENCES IN METABOLISM 
Sex difference is an important variable that should be considered in all areas of health-
related research (Tingen et al., 2010). It is well established that body size and body 
composition are sexually dimorphic (Rogol et al., 2002, Roemmich et al., 2002). 
Skeletal muscle mass is larger in males than in females (Janssen et al., 2000), while 
females have a higher percentage of fat mass than males (Wu and O'Sullivan, 2011, 
Loomba-Albrecht and Styne, 2009); this is characterized by a higher proportion of 
body fat in the gluteal-femoral region, whereas males have more body fat in the 
abdominal (visceral) region (Geer and Shen, 2009). Fat within the visceral area is 
associated with a statistically higher risk of hyperlipidemia, hypertension, IR (Hirosumi 
et al., 2002), and T2D (Duman et al., 2003). 
 
The prevalence of abnormalities of glucose metabolism has been estimated to be higher 
in middle-aged men than in age-matched women in (Kuhl et al., 2005) which might 
                                                                                                                                                                               Kamal Yassin 2011 
 
9 
 
indicate that sex dependent hormones play a role in this context. This notion is 
supported by animal studies showing that estrogen receptor knockout mice develop 
fatty liver, hepatic IR and impaired glucose tolerance (Kaye et al., 2006).  Based on 
previous studies (Tarnopolsky and Ruby, 2001), males might be predicted to more 
rapidly mobilize hepatic carbohydrates as compared to females. Moreover, when 
estrogen levels decrease, for example in the menopausal state, inter-sex differences 
decrease and women develop an increase in visceral fat (Goodpaster et al., 2005, 
Nicklas et al., 2004). 
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2 AIMS 
The general aim of this thesis was to investigate factors modulating glucose 
homeostasis in healthy and diabetic rats.  
Specific aims in the individual papers were: 
• To elucidate the direct effect of an extract of a Southeast-Asian herb 
Gynostemma pentaphyllum (GP) on hepatic glucose output in spontaneously 
type 2 diabetic Goto-Kakizaki (GK) rats. 
 
• To explore the effects of shikonin, a naphthoquinone derived from a Chinese 
plant, on total body glucose homeostasis in GK rats, and to investigate the 
effects of shikonin on glucose uptake and the mechanisms of its action in L6 
skeletal muscle cells. 
 
• To study the effect of a non-hematopoietic erythropoietin analogue ARA290 on 
glucose homeostasis in GK and Wistar rats and to explore the mechanism of 
action that underlies the anti-diabetic effects of ARA290 in GK rats.  
 
• To investigate sex differences in carbohydrate and lipid metabolism in the rat 
liver. 
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3 MATERIALS AND METHODS 
This section gives a general commentary of some of the methods central to the work 
presented in this thesis. More detailed descriptions of these and other methods used can 
be found in the corresponding papers. 
 
3.1 ANIMALS  
3.1.1 Wistar rats (W) 
Normal Wistar rats (W) were purchased from a commercial breeder (Scanbur BK, 
Sollentuna, Sweden) and used as non-diabetic controls (Paper III). 
 
3.1.2 Sprague-Dawley rats (SD) 
Male and female rats Sprague-Dawley rats (SD) rats were purchased from a 
commercial breeder (Scanbur BK) (Paper IV). 
 
3.1.3 Goto-Kakizaki rats (GK) 
The Goto-Kakizaki (GK) rat is a model of hereditary type 2 diabetes developed by 
selective breeding of normal Wistar (W) rats with a slight impairment of glucose 
tolerance. Repetition of the selective breeding resulted in rats exhibiting spontaneous 
non-obese diabetes. The GK rat develops hyperglycemia post-natally and maintains 
moderately enhanced plasma glucose levels during its lifetime. In common with human 
T2D, glucose intolerance in the GK rat is due partly to impaired insulin secretion, but 
also to IR in target tissues.  
In this thesis (Papers I, II and III) GK rats were studied and investigated for factors 
modulating glucose homeostasis. The GK rats used were bred at our department 
(Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, 
Sweden). 
All animal experiments were approved by the regional Ethics Committee on Animal 
Experiments. 
 
3.2 TREATMENTS  
3.2.1 Gynostemma pentaphyllum (GP)   
The GP extract used in our study was produced by from whole GP plants, collected by 
the Institute Materia Medica (Hanoi, Vietnam) from the Vietnamese mountains. Plant 
extract were prepared by boiling in water for 2 hours, after which concentrated ethanol 
(70%) was added to remove impurities by distillation at low pressure. The resulted 
material was ground into a powder to form soluble tea particles. 
In paper I, we investigated GP’s anti-diabetic effects in GK rats, and explored the 
observed improvement in hepatic insulin sensitivity. GP extract or green tea placebo 
were administrated orally at a dose of 800 mg/kg b.w. to unanesthetized GK rats by 
gavage through an enteral feeding tube (polyvinyl chloride, sterile VYCON, Lab. 
Pharmaceutiques Vycon, Ecouen, France). The administrations were performed twice 
daily for three days or three weeks.  
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3.2.2  Shikonin 
In paper II, we examined the effect of shikonin (Interchem, NJ, USA) on glucose 
uptake in skeletal muscle cells in vitro, and on total body glucose homeostasis in 
diabetic Goto-Kakizaki rats.In the latter in vivo experiments, intraperitoneal (i.p.) 
vehicle (DMSO/olive oil) (9:1), was administrated initially once daily for 4 days. One 
week after vehicle administration, shikonin were similarly administered to the same 
GK rats at a dose of 10 mg/kg b.w. 
 
3.2.3 ARA290 (Erythropoietin analogue) 
In paper III, we studied the effects of ARA290 on different aspects of glucose 
homeostasis in GK rats and non-diabetic control rats. ARA290 at a dose of 30 µg/kg 
b.w., or placebo were administered s.c. to GK and matched Wistar (W) rats once daily 
for four weeks. 
 
3.3 TOLERANCE TESTS  
3.3.1 Intraperitoneal glucose tolerance test (IPGTT) and insulin 
response 
Intraperitoneal (i.p.) glucose tolerance tests (IPGTTs) were performed in overnight-
fasted rats. Blood samples for determination of glucose (about 20µl/sample) were taken 
after a small tail incision. Plasma glucose  concentrations were measured  by 
glucometer (Accu-Chek Aviva) at 0, 15, 30, 60, and 120 minutes after an i.p. injection 
of glucose (2 mg/g body weight; Glukos APL 500 mg/ml) (Paper I). In addition, in 
paper III, blood samples were collected at 0 and 30 min during the IPGTT for insulin 
analyses using radioimmunoassay (Herbert et al., 1965).  
 
3.3.2 Intraperitoneal pyruvate tolerance test (IPPTT) 
Intraperitoneal pyruvate tolerance tests (IPPTTs) was carried out in overnight-fasted 
GK rats. Plasma glucose concentrations were obtained at 0, 15, 30, 60, and 120 minutes 
after an i.p. injection of pyruvate (2 mg/g body weight; sodium pyruvate, SIGMA) 
(Papers I and III). 
3.3.3 Subcutaneous (s.c.) insulin tolerance test (SCITT) 
For the SCITT, insulin was injected i.p. at a dose of 0.5 U/kg in overnight-fasted 
(Papers I and III) and non-fasted (Paper II) GK rats. Plasma glucose levels were 
measured before the injection of insulin at 0 min, and then every 15 minutes for 2 hours 
and every 30 minutes for further 2 hours. 
 
3.4 IN SITU PERFUSION OF RAT LIVER 
Liver perfusion in situ is a valuable technique for the study of hepatic metabolism. 
Rats were anesthetized with an intraperitoneal injection of ketamine (Pfizer AB, Täby, 
Sweden) at a dose of 60-70 μg/g b.w. Subsequently, rats under went median 
laparotomy and the portal vein was identified and cannulated. Thoracotomy was then 
performed, and a second cannula was placed in the inferior vena cava via the right 
atrium. Rat livers were perfused in situ without recirculation via the portal vein using 
Krebs-Henseleit bicarbonate buffer (118.4 mM NaCl, 4.7 mM KCl, 1.9mM CaCl2, 1.2 
mM MgSO4, 1.2 mM KH2PO4 and 25 mM NaHCO3, equilibrated with 95% O2 and 5% 
CO2, pH 7.4) with 0.2% bovine serum albumin (BSA), and 10 mM HEPES (Doi et al., 
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2001) in a 37°C cabinet. The perfusion pressure was constant with a flow rate of 3.0-
4.0 ml/min/g liver under basal conditions. Perfusate was drained from the inferior vena 
cava. Samples were collected every 2 min after a brief period of initial perfusion to 
completely remove blood from the liver. Perfusion then was continued for a further 8-
15 min (Papers I and IV). In paper I, hepatic glucose production was stimulated by   
adrenalin (Merck AB NM, Stockholm, Sweden) which was added  into the perfusion 
medium (KRB) to a final concentration  of  50 nM. The glucose levels in the perfusate 
were measured by a Glucometer (YSI 2300, STST PLUS, VWR).  
 
3.5  ISOLATED PANCREATIC ISLETS 
3.5.1 Insulin secretion (Paper III) 
After 4 weeks of treatment with either ARA290 or placebo, GK rats were sacrificed by 
decapitation. Islets were isolated by collagenase digestion of the pancreas (Hoa et al., 
2004). Directly after isolation, islets were incubated to study glucose-induced insulin 
release. After a pre-incubation period of 30 min at 37°C in Krebs-Ringer bicarbonate 
buffer solution (KRB), supplemented with 2 mg/ml bovine albumin, 10 mM HEPES 
and 3.3 mM glucose, pH 7.4, batches of three islets were incubated for 60 min at 37°C 
in 200 µl of KRB as above, and with either 3.3 or 16.7 mM glucose. After incubations, 
aliquots of the media were taken for radioimmunoassay of insulin. 
3.5.2 Intracellular levels of Ca2+ concentration [Ca2+]i in islets (Paper III) 
Islets were incubated with 2 µM fura-2 AM and changes in [Ca2+]i, i.e. the fluorescence 
ratio at 355/380 nm, were analyzed on a microscope consisting of a Zeiss Axiovert 
200M with a fluorescence imaging system, using Andor iQ software with an Andor 
iXon DV887DCS-BV camera and a Cairn monochromator for excitation (Andor 
Technology plc, Belfast, UK) (Healy et al., 2010, Yang and Gillis, 2004).    
 
 
3.6 GLYCOSYLATED HAEMOGLOBIN (HBA1C) MEASUREMENTS 
Red blood cells were lysed  and the proteins desalted using 100 µL OMIX C4 tips 
(Agilent Technologies, Santa Clara, CA), using the manufacturer’s protocol, with 10 
loading cycles and elution with 10 µL 75% MeOH. Mass spectra were acquired on a 15 
tesla solariX Fourier transform ion cyclotron resonance mass spectrometer (Bruker 
Daltonics, Bremen, Germany). After desalting, 5 µL of each tip eluate was diluted with 
95 µL H2O: MeOH 1:1 (v/v) and 0.1% formic acid and infused directly into the 
electrospray source at 2 µL/min using the built-in syringe pump and a 100 µL syringe. 
For HbA1c quantitation, 64 full profile spectra of 1 M data points (1.9 s transient) 
covering m/z 829-1,000 were averaged, zero-filled (1X) and sine square apodized 
(Marshall et al., 1998). Quadruple transmission was optimized at the mid-point of the 
m/z range. The resolving power (m/Δm, FWHM) of the hemoglobin chains was 
~150,000. Wider range spectra (m/z 598-2,000) were also acquired to characterize the 
protein contents of the sample and the charge state distributions of the different 
hemoglobin chains. All spectra were acquired in broadband mode and externally 
calibrated using the heme monomer and dimer peaks. 
After conversion of full profile data to mzXML (Pedrioli et al., 2004), Xtractor (Selman 
et al., 2010) as used to extract the area under the six most abundant isotopic peaks of 
the [M+18H]18+ α-chain (UniProtKB HBA_RAT, m/z ~845.3), β-chain (UniProtKB 
HBB1_RAT, putatively with the T124S mutation, m/z ~880.6), the same β-chain with a 
glucose adduct (m/z ~889.6) and corresponding background signal from an empty 
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region of the spectra. The fraction of glucose adduct was reported as the ratio of the 
signal of the β-chain with a glucose adduct to the total β-chain signal. 
 
 
3.7 HEMATOCRIT MEASUREMENTS   
Blood samples were collected in EDTA-anticoagulated tubes, and hematocrit was 
measured using an automated blood analyzer (Scandivet AB, Enköping, Sweden). 
 
3.8 EXPRESSION PROFILING USING MICROARRAYS 
The microarray is a multiplex technology used to determine transcript profile. In paper 
IV, microarrays containing 70 mer oligonucleotide probes for 27 649 rat protein-coding 
genes were fabricated and used to obtain transcript profiles. Total RNA from each 
sample wasDNase-treated using RNeasy MiniElute Cleanup kits (QIAGEN), and RNA 
concentrations measured using a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies Inc.). The microarray experiments were performed using the Pronto!TM 
Plus Direct Systems (Corning Incorporated and Promega Corporation, NY), according 
to the manufacturer’s instructions using 5 µg total RNA from each sample. Samples 
from male rat livers were hybridized with female samples on individual arrays to obtain 
a direct effect of sex on hepatic gene expression. Each hybridization compared Cy3-
labeled cDNA reverse transcribed from RNA isolated from female rat livers with Cy5-
labeled cDNA isolated from male livers. Each experiment was analysed using 
individual samples and dye-swopping (Stahlberg et al., 2004). 
Identification of sex-dependent genes was performed usingSAM 1.21 (Significance 
Analysis for Microarray) software incorporated into Microsoft Office Excel. A 5% 
false discovery rate was used as a first cut-off. Genes with a greater than 1.5-fold 
difference between the sexes were considered as being sex-dependent. The results are 
presented as the mean of at least three independent determinations.  
 
3.9 AKT AND AMPK PHOSPHORYLATION 
Whole liver cell lysates were obtained by homogenizing 1 g of liver in 3 ml RIPA 
buffer. The resulting supernatants were collected and the degree of insulin signaling 
was analysed by measuring the degree of insulin-dependent phosphorylation of Akt. 
Akt activation was determined by analysing the amount of phosphorylated Akt (p-Akt- 
Ser473) in relation to total Akt, using commercially available ELISA kits (Biosource). 
The degree of AMPK phosphorylation was determined using antibodies detecting p-
AMPK-Thr172 or AMPK (1:1000) from Cell Signaling. Densitometry analyses were 
performed using the software Quantity One 4.6.5 Basic (Bio-Rad Laboratories) to 
compare the amount of phosphorylated AMPK (p-AMPKThr172) in relation to total 
AMPK. 
 
3.10 NMR SPECTROSCOPY 
Liver perfusate samples (500 μl) were mixed with 50 μl standard solution of Hexa 
deutero-4, 4-Dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA), purchased 
from Onyx Scientific Ltd (Sunderland, United Kingdom). 
The NMR spectroscopic measurements were made on a Bruker 600 MHz instrument 
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(Bruker BioSpin, Rheinstetten, Germany) operating at 600.23 MHz, equipped with a 5 
mm inverse probe and a SampleJet sample changer. 1H-NMR spectra were acquired 
using a Carr-Purcell-Meiboom-Gill (CPMG) spin-echo sequence to attenuate broad 
signals arising from macromolecular components (Meiboom and Gill, 1958). 
Altogether 512 transients were acquired into 64 K data points using a spectral width of 
12019 Hz with a spin echo loop time of 76.8 ms and relaxation delay of 2.0 s, with a 
total repetition time of 4.82 s. Suppression of the water resonance was achieved by 
presaturation during the relaxation delay and the spin-echo loop.  
 
 
3.11 REAL–TIME PCR (RT-PCR) 
The RT-PCR method permits amplification and quantification of a targeted DNA 
molecule. In paper IV, total RNA was treated with DNase (RQ1) and reverse 
transcribed using iScript™ reverse transcriptase and 5x buffer for First Strand cDNA 
synthesis (Bio-Rad Laboratories AB). The purity of the synthesized cDNA was 
checked by agarose gel electrophoresis. Each first strand cDNA served as a template in 
a 20 μl real-time PCR reaction mix containing the primers for the gene of interest and 
iQ SYBR Green Supermix (Bio-Rad Laboratories AB). Quantification of gene 
expression (Gustavsson et al., 2009) was performed according to the manufacturer’s 
protocol using a DNA Engine Opticon™2 real-time PCR detection system (MJ 
Research). 
The protocol was validated for each gene of interest by checking melting curves for the 
absence of primer–dimers and other unwanted amplicons.  
The level of individual mRNAs was normalized with the level of the housekeeping 
gene ribosomal protein long-chain protein Pθ (RPLP).  
 
3.12 WESTERN BLOT 
Western blotting is a technique to identify proteins with the help of specific antibodies. 
This method was used to analyze proteins from L6 cells (Paper II). 
Cells were serum-starved overnight before each experiment and exposed to drugs for 
different times and at different concentrations (Lindquist et al., 2000). After 2 h of 
shikonin or insulin stimulation, the L6-cells were lysed directly in the well by the 
addition of 80 μl  65°C SDS sample buffer (62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% 
glycerol, 50 mM dithiothreitol, and 0.1% bromphenol blue). Cells were scraped, 
transferred to an Eppendorf tube on ice, sonicated for 10 s and heating to 100°C for 5 
min.  
Aliquots of the samples were separated on a 12% polyacrylamide gel and 
electrotransferred to a Hybond-P PVDF membrane (pore size 0.45 μm; Amersham 
Pharmacia Biotech) with a semidry electroblotter . After transfer, the membranes were 
allowed to soak in Tris-buffered saline for 5 min, followed by quenching of nonspecific 
binding (1 h at room temperature in 5% nonfat dry milk, 0.1% Tween 20 in Tris-
buffered saline).  
Membranes were probed using AMPK, phospho-AMPK (Thr172), Akt, phospho-Akt 
(Ser473), or phospho-Akt (Thr308), (diluted 1:1000 except phospho-AMPK diluted 
1:500) antibodies. Protein-antibody complexes were detected using a secondary 
antibody (HRP-linked anti-rabbit IgG, diluted 1:2000) and chemiluminescence (ECL, 
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Amersham Pharmacia Biotech). All antibodies were purchased from Cell Signalling. 
The bands were scanned and quantified by the software MacBiophotonics ImageJ. 
 
3.13 L6 CELL CULTURE AND GLUCOSE UPTAKE 
L6 myoblasts can be differentiated into myotubes and are commonly used for studies of 
glucose uptake. In paper II, L6 cells (from ATCC) were grown in Dulbecco's modified 
Eagle’s medium (DMEM) containing 4.5 g/liter glucose, supplemented with 10% fetal 
bovine serum (FBS), 10 mM HEPES buffer, 2 mM L-Glutamine, 50 U/ml penicillin 
and 50 µg/ml streptomycin in a 37°C incubator with 8% CO2. Upon reaching 
confluence, differentiation was induced by media containing 2% (v/v) FBS for 7 days, 
with medium changes every second day. Differentiated L6 myotubes were treated with 
1 µM shikonin or 1 µM insulin for 2 h or 20 h. Glucose uptake was measured using the 
2-deoxy-[3H] D-glucose method. Briefly, cells were serum-starved overnight before 
each experiment and glucose uptake was measured on day 7. The medium was changed 
to serum-free media the evening before the experiments, and changed to fresh medium 
on the morning 2 h or 20 h before cells were exposed to shikonin treatment. Cells were 
washed twice in warm PBS before a change of media, and drugs were placed in 
DMEM devoid of glucose for 10 min. 2-Deoxy-[3H] D-glucose (50 nM) was added for 
6-10 min at 37°C. The reactions were terminated by washing twice in ice-cold PBS. 
Cells were incubated in 0.2 M NaOH for 1 h at 60°C, and the samples were transferred 
to scintillation vials with scintillant and allowed to sit at room temperature for 1 h 
before being counted (Merlin et al., 2010, Hutchinson and Bengtsson, 2006).  
 
3.14 ATP LEVEL MEASUREMENTS 
L6-myotubes were serum-starved overnight and new medium was added for 2 h before 
stimulation with drugs for 2 h. Measurement of the AMP:ATP ratio was performed on 
day 7. One ml of boiling water was added to each well of a six-well plate, and the cells 
were scraped and boiled (3 min). Samples were centrifuged (12,000 g, 4°C, 10 min) to 
pellet cell debris, and the supernatant fractions were used for further analyses. Each 
sample was diluted 1:10, three aliquots (20 μl) were transferred to a white 96-well 
plate, and 30 μl of either reagent A (aqueous tricine buffer [40 mM, pH 7.8], MgSO4 [8 
mM], EDTA [0.17 mM], which measures total cellular ATP), reagent B (reagent A 
buffer supplemented with dCTP [0.1 mM], nucleoside-5′-diphosphate-kinase [10 
U/ml], which converts the ADP in a given sample to ATP) or reagent C (reagent B 
supplemented with myokinase [10 U/ml], which converts the AMP and ADP in a given 
sample to ATP) added for measurement of ATP, ADP and AMP, respectively. Samples 
were incubated for 12 h at 37°C, after which the reactions were terminated by boiling 
for 5 min, and then 50 μl of luciferin–luciferase reagent (aqueous tricine buffer [25 
mM, pH 7.8], MgSO4 [5 mM], EDTA [0.1 mM], D-luciferin [0.5 mM], luciferase [10 
μg/ml], dithiothreitol [2 mM], CoA [0.5 mM]) were added to each well. ATP levels 
were measured in duplicate using a commercial kit (ATP determination kit time stable 
assay; Biaffin, Kassel, Germany). Results are expressed as nanomoles ATP per 
milligram protein (Merlin et al., 2010, Hutchinson and Bengtsson, 2006).  
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3.15 OXYGEN CONSUMPTION 
Oxygen consumption was measured in the absence or presence of 1 µM shikonin in 
differentiated L6 cells and skeletal muscle mitochondria. L6 cells were harvested by 
trypsin digestion, while mitochondria were isolated from mouse muscles (Shabalina et 
al., 2010). Oxygen consumption rates were monitored with a Clark-type oxygen 
electrode (Yellow Springs Instruments Company, Yellow Springs OH, U.S.A.) in a 
sealed chamber at 37°C. L6 cells were added to a magnetically stirred oxygen electrode 
chamber containing DMEM in a final volume of 1.1 ml. The output signal from the 
oxygen electrode amplifier was collected by a PowerLab/ADInstrument (application 
program Chart v5.1.1.). The Chart data files were converted to absolute values, based 
on an oxygen content of 217 nmol of O2 per ml of water and on the number of cells 
used. For calculation of stable oxygen consumption rates, mean values during 1 min 
were obtained from these recordings.  
 
 
3.16 INTRACELLULAR LEVELS OF CA2+ CONCENTRATION [CA2+]I IN L6 
CELLS  (PAPER II) 
Cytosolic free [Ca2+] ([Ca2+]i) was measured during exposure to shikonin (1 µM) or 
insulin (1 µM) using the fluorescent ratiometric Ca2+ indicator indo-1. Cells were 
loaded with indo-1 by exposing them to indo-1-AM (8.3 mM, Invitrogen) for 20 
minutes, followed by at least 20 minutes of washing. Indo-1 was excited with light at 
360 nm, and light emission at 405±5 and 495±5 nm was measured with two 
photomultiplier tubes. The ratio (R) of the light emission at 405 nm to that at 495 nm 
was converted to [Ca2+]i (Grynkiewicz et al., 1985). After establishing a baseline, 
shikonin or insulin was added. 
 
 
3.17 IMMUNOCYTOCHEMISTRY 
L6 cells stably transfected with GLUT4myc were plated in 4 well culture chamber 
slides (BD Biosciences, Franklin Lakes, BJ). Cells were serum-starved 16 h before 
stimulation with insulin or shikonin. After stimulation, the cells were washed with PBS 
and fixed for 5 min with 4% formaldehyde in PBS, and quenched with 50 mM glycine 
in PBS for 10 min. Cells were blocked with 5% BSA in PBS for 1 h and incubated with 
Myc-tag primary antibody solution (1:200 dilution in 1.5% BSA in PBS) at 4 oC 
overnight, followed by washing with PBS and a 1 h incubation at room temperature 
with Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody (1:500 
dilution, 1.5% BSA in PBS). Slides were washed with PBS and mounted with ProLong 
Gold antifade reagent (Invitrogen). Images were observed in a confocal microscope, 
ZEISS LSM 510 META. Quantification of immunocytochemistry images was 
performed by using the ImageJ program (NIH). 
 
 
3.18 STATISTICAL ANALYSIS 
In papers I, II and III, the results have been calculated as mean ± SEM, and 
comparisons of the means have been performed by the unpaired Student´s t-test,  
ANOVA with the Tukey post hoc-test, or by the paired Student’s t-test, using 
Bonferroni´s correction for multiple testing, as appropriate.  
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In paper IV, two-way ANOVA was performed to determine whether there were 
significant effects of sex, fasting or insulin treatment on measured variables, or 
significant interactions i) between sex and fasting, or ii) between sex and insulin. 
Subsequently, if the interaction was found to be significant, one-way ANOVA was 
conducted and multiple comparisons with Fisher’s Least Significant Difference (LSD) 
test was employed to compare i) 4h-fasted males and females and the 12 h fasting 
effect, or ii) saline-treated males and females and the insulin effect in males and 
females. Friedman’s non-parametric test was utilized to determine the effect of insulin 
treatment or a sex effect in 1H-NMR metabolite data. Where indicated, groups were 
also compared using Student’s t-test. P-values < 0.05 were considered significant. 
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4 RESULTS & DISCUSSION 
 
4.1 HERBAL EXTRACT OF GYNOSTEMMA PENTAPHYLLUM 
DECREASES HEPATIC GLUCOSE OUTPUT IN TYPE 2 DIABETIC 
GOTO-KAKIZAKI RATS (PAPER I) 
In this paper, we investigated the effect of GP extract on modulating hepatic glucose 
production in GK rats treated orally with GP or placebo extract daily, during three days 
or three weeks. We found that the three-week, but not the three-day, treatment with GP 
reduced PG levels in GK rats (p= 0.027), whereas PG levels were not decreased after  
placebo treatment. After three weeks of treatment, glucose tolerance evaluated by an 
intra-peritoneal glucose tolerance test was improved in the GP-treated, compared to the 
placebo-treated, group (areas under the glucose curves, AUCs; p = 0.013; Fig.4a). In an 
intra-peritoneal pyruvate tolerance test, the glucose response from minute 15 to minute 
120 was lower in the GP group (p< 0.05; Fig.4b).  
 
In liver perfusions, the basal HGO in GP treated rats was 27% lower than that of the 
placebo group. Moreover, the AUCs for hepatic glucose output (HGO) during the first 
18 min (0-18 min) were decreased in GP-treated rats, compared with placebo-treated 
rats (p<0.05).  
 
Fig. 4: Mean of plasma glucose levels during IPGTT (a) and IPPTT (b) after three weeks of treatment of 
GK rats with GP. 
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In addition, the response to an infusion of 50 nM adrenaline after 8 min of the perfusion 
(8-18 min) increased HGO in all rats, although this effect of adrenalin tended to be 
suppressed in GP extract-treated rats, compared to placebo-treated rats. Three weeks of 
GP treatment significantly reduced hepatic glycogen content, but not glycogen synthase 
activity, compared to placebo group (p<0.007). GP has been reported to exert a variety 
of effects, such as anti-oxidant (Li et al., 1993), lipid lowering (la Cour et al., 1995), 
anti-inflammatory (Lin et al., 1993, Huang et al., 2007), anti-carcinogenic (Lu et al., 
2008, Chen et al., 2006) and pro-apoptotic effects (Wang et al., 2002). In our previous 
investigations in type 2 diabetic patients, treatment with GP extract (Huyen et al., 2010) 
induced a potent anti-hyperglycemic effect. Insulin sensitivity was enhanced, as 
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demonstrated by reduced HOMA-IR, and fasting PG levels were significantly 
decreased after 12 weeks of treatment. 
 
In our study, three days’ treatment with GP extract did not change the PG levels, while 
long-term three-week treatment induced a significant decrease in PG levels, 
improvements in glucose tolerance, and reductions in HGO, compared to placebo-
treated rats. However, in the insulin sensitivity test, which reflects insulin sensitivity 
mainly in extra-hepatic tissues, no differences were observed between the two groups, 
suggesting that the primary effect of GP extract is unlikely to be exerted via extra-
hepatic tissues, i.e. mainly skeletal muscle. Therefore, these findings indicate that GP-
induced improvements in glucose tolerance in GK rats is due to an effect in the liver, 
which may at least partly due to decreased HGO. Insulin decreases HGO by activating 
glycogen synthesis and glycolysis, and by suppressing gluconeogenesis (Cherrington et 
al., 2007). Glycogen is the intracellularly stored form of glucose, and its levels in 
various tissues, particularly in the liver and skeletal muscle, reflect the action of insulin 
in stimulating glycogen synthase and inhibiting glycogen phosphorylase (Edgerton et 
al., 2009). We have shown that hepatic glycogen synthase activity after three weeks of 
treatment did not differ between GP-treated and placebo-treated rats. Nevertheless, the 
hepatic glycogen content after GP extract treatment was significantly lower than that 
after placebo treatment. In the liver, is controlled by a number of different mechanisms. 
Phosphotyrosine phosphatase 1B (PTP1B) is known to negatively modulate insulin 
action on hepatic glucose metabolism through tyrosine dephosphorylation of the insulin 
receptor and/or insulin receptor substrates (Haj et al., 2005). Interestingly, recent 
experimental studies demonstrate that GP extract inhibits PTP1B activity, which may 
lead to enhanced insulin sensitivity and thereby improved glucose tolerance (Hung et 
al., 2009, Xu et al., 2010). 
 
Furthermore, a recent study has shown that hepatic glycogen content was significantly 
reduced in PTP1B -/- transgenic mice, as compared to wild-type controls (Escriva et al., 
2010). Therefore, it can be speculated that GP extract improves hepatic insulin 
sensitivity to some extent through inhibiting PTP1B. Since in the GP extract-treated 
GK rats the pyruvate tolerance test showed a decreased glucose response, it seems 
likely that the improvement in hepatic insulin sensitivity is partly accounted for by a 
reduction of gluconeogenesis. 
 
In conclusion, the results of this study demonstrates that three-weeks’ treatment of GP 
extract exerted anti-diabetic effects in GK rats, reducing plasma glucose levels and 
HGO, suggesting that GP improves the hepatic insulin sensitivity by suppressing 
gluconeogenesis. 
 
4.2 SHIKONIN INCREASES GLUCOSE UPTAKE IN SKELETAL MUSCLE 
CELLS AND IMPROVES PLASMA GLUCOSE LEVELS IN DIABETIC 
GOTO-KAKIZAKI RATS (PAPER II) 
In this paper, we examined the possible effect of shikonin on glucose uptake in skeletal 
muscle as well as on total body glucose homeostasis. 
 
Our results revealed that stimulation with shikonin (1μM) for 2 h increased glucose 
uptake in L6-myotubes (p<0.01), a response which was of the same magnitude as that 
obtained following insulin treatment (1μM, p<0.01) (Fig. 5). Stimulation for 20 h with 
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shikonin or insulin at the same concentrations tended to induce increases in glucose 
uptake but the improvment was not statistically significant. 
 
In L6 myotubes, shikonin treatment (1μM, 2 h) did not affect phosphorylation of Akt, 
whilst insulin treatment (1 μM, 2 h) increased phosphorylation of Akt at residues s473 
or t308. Moreover, shikonin treatment (1 μM, 2 h) did not mimic the effect of the 
AMPK activator AICAR (2 mM, 2h), which increased AMPK phosphorylation at 
residue t172 by ~2 fold. Furthermore, shikonin did not induce any change in the 
AMP:ATP ratio. Addition of 1 μM shikonin increased oxygen consumption in intact L6 
muscle cells. Shikonin had no effect on isolated skeletal muscle mitochondria, either in 
the presence or absence of the substrate pyruvate, indicating that shikonin does not act 
directly on mitochondria. Shikonin increased the intracellular levels of calcium in L6 
cells. However, the cell-permeable calcium chelator, BAPTA-AM (5 μM), blocked 
shikonin-stimulated glucose uptake. Furthermore, we found that shikonin stimulated 
the translocation of GLUT4 from intracellular vesicles to the cell surface in L6 
myotubes (Fig. 6).  
 
 
 
 
        
 
 
    
 
 
  
 
 
   
 
  
  
 
 
 
 
        
  
      
  We also investigated the effect of shikonin on glucose homeostasis in diabetic GK rats. 
GK-rats were treated for 4 days with a daily i.p. injection of shikonin (10 mg/kg). In 
these rats, PG levels were significantly lowered on the 2nd and 4th days, compared to 
day 1 (p < 0.01 and p<0.001, respectively) (Fig. 7). Also, the areas under the glucose 
curve (AUCs) were significantly lower in shikonin-treated rats compared to control rats 
(p=0.014). In a s.c. insulin tolerance test (SCITT), administration of insulin reduced PG 
concentrations in all rats. The plasma glucose levels prior to insulin injection were 
lower in shikonin-treated rats compared to control rats (p =0.007) (Fig. 8).  The total 
AUCs from 0 to 240 min were similar in shikonin-treated and control rats.  However, 
for the period corresponding to 30-240 min after injection of insulin, the AUCs were 
lower in shikonin-treated rats, compared to control rats (p<0.02). 
 
Shikonin is a naphtoquinone derivative from the plant Lithospermum erythrorhizon that 
inhibits the formation of the NADPH oxidase (Pageorgiou V.P et al., 1999). The 
compound has been shown to stimulate glucose uptake in 3T3-L1 adipocytes, primary 
rat adipocytes and cardiomyocytes (Kamei et al., 2002). 
 
In L6 myotubes, shikonin and insulin increase glucose uptake to the same extent.  
 
 
 
 
 
 
 
 
Fig.5: Shikonin increases glucose 
uptake in L6 myotubes; cells were 
treated with 1µM shikonin (sh) or 
1µM insulin for 2 h. Graph shows 
mean ± SEM for 7 rats ** P,0.01 
***P,0.001 
 
Fig.6: Shikonin stimulates translocation of 
 GLUT 4 expressed as % of basal. Graph 
shows mean± SEM of 3 rats. 
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However, unlike insulin, shikonin did not affect Akt-phosphorylation, suggesting that 
in L6 myotubes, shikonin increases glucose uptake independent of Akt 
phosphorylation, via a pathway which is distinct from that activated by insulin. 
Conversely, in 3T3-L1 adipocytes, shikonin has been shown to increase glucose uptake 
by increasing Akt-phosphorylation (Kamei et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measurement of AMP/ATP-levels showed no differences between control- and 
shikonin-treated myotubes, nor was any increase in the phosphorylation of AMPK 
detected following shikonin treatment, indicating that shikonin does not act via AMPK. 
The increase in intracellular calcium levels which occurs during muscle contraction has 
been suggested to increase glucose uptake (Rose and Richter, 2005). Interestingly, our 
experiments in L6 myotubes showed that shikonin treatment does in fact lead to an 
increase in intracellular free calcium levels. A well-characterized molecular mechanism 
which leads to increased glucose uptake into skeletal muscle is the increased content 
and translocation of the glucose transporter GLUT4 (Koistinen et al., 2003, Chibalin et 
al., 2000). GLUT4-translocation has previously been suggested to be calcium-
dependent, both with regards to its activation by insulin, as well as with respect to 
GLUT4 translocation resulting from muscle contraction (Niu et al., 2010). In attempts 
to identify further mechanisms in L6 myoblasts, we found that shikonin stimulated the 
translocation of GLUT4 from intracellular vesicles to the cell surface. 
 
In our in vivo experiments in diabetic GK rats, shikonin improved glucose tolerance, as 
mainly reflected by lower fasting PG levels after shikonin treatment compared with 
placebo treatment. In an insulin tolerance test, the decrease in PG levels was similar in 
shikonin-treated and control rats. However, the absolute plasma glucose levels in the 
SCITT from 0 to 240 min were lower in shikonin-treated rats, which indicates that the 
effects of shikonin and insulin are additive.  
 
In conclusion, shikonin increases glucose uptake in muscle cells via an insulin-
independent pathway involving increased intracellular calcium levels and GLUT4-
translocation. The beneficial effects of shikonin on glucose homeostasis demonstrate 
that the compound possesses properties that make it of considerable interest in the 
search for novel therapies for T2D. 
 
Fig.7: Shikonin’s effect on plasma glucose in 
GK rats treated with DMSO/oil or shikonin 
for 4 days .Graph shows mean ± SEM for 6 
rats.** P,0.01 for shikonin day 2 compared to 
day 1, ***P,0.001 for shikonin day 4 
compared to day 1. 
Fig.8: Shikonin’s effect on insulin sensitivity in 
 GK rats treated with DMSO/oil or shikonin  
for 4 days. Graph shows mean ± SEM for 6 rats. 
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4.3 THE NON-HEMATOPOIETIC ERYTHROPOIETIN ANALOGUE, 
ARA290, IMPROVES GLUCOSE TOLERANCE IN GK RATS, A 
MODEL OF TYPE 2 DIABETES (PAPER III) 
In this paper we studied the effects of the non-hematopoietic erythropoietin analogue, 
ARA290, on different aspects of glucose homeostasis in spontaneously diabetic Goto-
Kakizaki (GK) rats and non-diabetic control rats. 
 
In non-diabetic Wistar rats, neither non-fasting PG levels, nor the AUCs, differed 
between ARA290- and placebo-treated groups during the IPGTT. In ARA290-treated 
GK rats, non-fasting PG levels were lower in the 3rd and 4th weeks of treatment, as 
compared to placebo controls (p = 0.02 and p<0.05; respectively) (Table 1). Prior to 
treatment, IPGTTs were similar in both groups (Fig. 9A). Moreover, during the IPGTT, 
the total AUC was significantly lower in the 2nd and 4th weeks in ARA290-treated, 
compared to control, GK rats (p=0.003; Fig 9B, and p=0.02; Fig. 9C, respectively). 
However, the results of the SCITTs and IPPTTs were similar in ARA290-treated and 
control groups, indicating that treatment with ARA290 did not influence extra-hepatic 
and hepatic insulin sensitivity. In addition, the hematocrit was identical in both groups. 
In islets isolated from ARA290-treated GK rats, the insulin responses to high glucose 
concentrations in relation to basal glucose levels were significantly increased, 
compared to islets from the placebo-treated rats (p<0.05). Interestingly, in response to 
glucose stimuli, intracellular cytosolic calcium concentrations were enhanced in islets 
from ARA290-treated rats, compared to islets from the placebo-treated rats (p<0.0002). 
Moreover, addition of carbachol had an effect on intracellular calcium concentrations 
which was additive with the significant increases resulting from ARA290-treatment, 
compared to the placebo-treated rats (p<0.02). Similar effects were seen in response to 
a potassium chloride stimulus (p<0.02). 
 
 
Table 1:  
Plasma glucose levels (mM) in Wistar and GK rats, during 4 weeks of ARA290 (30µg/kg) and PBS 
treatment.Results are the mean±SEM; n, no of rats. W, week. *P<0.05 vs. control group (PBS) at the 
same week.  
                    
 
      
  n W0 W1 W2 W3 W4 
Wistar rats             
ARA290  6 5.6±0.2 5.9±0.1 6.3±0.2 6.3±0.2 6.3±0.2 
   PBS          6 5.7±0.2 5.8±0.2 6.5±0.3 6.4±0.2 6.3±0.2 
              
GK rats             
   ARA290            8 7.6±0.2 7.5±0.3 7.4±0.2 7.4±0.2* 8.0±0.2* 
   PBS 7 7.7±0.1 8.1±0.3 7.8±0.2 8.6±0.2 9.3±0.2 
              
 
        
Erythropoietin (EPO) is a cytokine that regulates hematopoiesis via its binding to the 
erythropoietin receptor (EPO-R). EPO-R has been shown to be present in nonerythroid 
tissues, including pancreatic islets (Frayling, 2007). In addition to its well-known 
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hematopoietic action, EPO has been shown to exert anti-inflammatory, anti-apoptotic 
and cytoprotective effects in a wide variety of cell types (Brines and Cerami, 2006). 
Evidence of inflammation and apoptosis has been observed in the pancreatic islets of 
patients with T2D, as well as in islets from animal models of the disease (Homo-
Delarche et al., 2006, Donath et al., 2003). Impaired β-cell function and insulin 
secretion play a primary role in T2D (Ostenson and Efendic, 2007, Frayling, 2007).  
Recently, EPO treatment was shown to protect against diabetes development in 
streptozotocin-induced and db/db mouse models of type 1 and type 2 diabetes,  
respectively, while exerting anti-apoptotic, anti-inflammatory, proliferative and 
angiogenic effects within the islets (Choi et al., 2010). 
 
Fig 9: Plasma glucose levels during IPGTTs (A) baseline, (B) after 2 weeks and (C) after 4 weeks of                                                                                                    
treatment. Graphs show mean ± SEM. 
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Our present results indicate that the improvements in non-fasting PG levels as well as 
in glucose tolerance in ARA290-treated GK rats could be due either to an enhancement 
of insulin sensitivity, and/or to increased insulin secretion. Since there were no 
significant differences between ARA290-treated and placebo-treated controls in their 
responses to either the pyruvate tolerance test or the insulin sensitivity test, it is not 
ARA290 
PBS
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likely that ARA290 exerts its action on insulin sensitivity in either the liver or extra-
hepatic tissues. Furthermore, as observed from the IPGTT results, fasting plasma 
insulin levels were not different between treated and control rats, which is in agreement 
with the concept that ARA290 does not improve glucose homeostasis by acting on the 
liver. It appears likely that ARA290–induced improvement of glucose tolerance in GK 
rats can be accounted for by an effect on the pancreatic β-cells, i.e. the stimulation of 
insulin release. 
 
In pancreatic β-cells, intracellular calcium stores are well known to be important in 
regulating calcium homeostasis and to be engaged in insulin secretion (Tengholm and 
Gylfe, 2009). Our measurements of intracellular calcium concentrations revealed that 
islets from ARA290-treated rats had higher Ca2+ levels in response to several 
secretagogues, suggesting that the ARA290-induced improvement of insulin secretion 
could be due to an enhancement of extracellular calcium influx leading to increased 
cytosolic calcium concentrations. 
 
It is known that exogenous erythropoietin increases hematocrit levels (Fenjves et al., 
2003). In contrast to previous studies with EPO (Choi et al., 2010, Ogunshola et al., 
2006), in which treatment enhanced hematocrit to almost 75%, the hematocrit in GK 
rats was entirely normal after four weeks of ARA290-treatment. 
 
Collectively, we can conclude that treatment with ARA290 significantly improved 
glucose tolerance in diabetic GK rats. This effect in GK rats is rather likely due to an 
improvement of glucose-stimulated insulin release. The mechanism underlying this 
improved insulin secretion seems to be mediated by β-cell membrane depolarization 
and the attendant increases in intracellular calcium concentrations which participate in 
the signaling pathway for glucose-stimulated insulin secretion. 
 
    
4.4 SEX-DIFFERENT HEPATIC GLYCOGEN CONTENT AND GLUCOSE 
OUTPUT IN RATS (PAPER IV) 
In this paper, we characterized sex differences in carbohydrate and lipid metabolism in 
the rat liver. Out of approximately 3 500 gene products detected in the rat liver, 22% of 
the genes expressed were identified as being sex-dependent (11% being male-
predominant and 11% female-predominant), as determined by whole-genome 
microarrays. 
In line with previous reports (Soler-Argilaga and Heimberg, 1976, Soler-Argilaga et al., 
1975), female-predominant genes were involved in hepatic uptake of long-chain fatty 
acids, synthesis of TG, and assembly of VLDL particles. Genes involved in 
mitochondrial and peroxisomal oxidation of FA were shown to be male-predominant. 
In addition, genes involved in glucose uptake and glycogen synthesis were more highly 
expressed in males. 
Male and female rats, fasted for either 4h or 12h, were compared with regards to 
differences in the levels of mRNAs encoded by genes related to metabolism in rat liver.  
Greater sex differences in hepatic gene expression were shown in 12 h -fasted rats, as 
exemplified by higher levels of acetyl-CoA carboxylase 1 (ACOX1), carnitine 
palmitoyltransferase 1a (CPT-1a), UDP-glucose pyrophosphorylase 2 (UGP2), 
glutamate oxaloacetate transaminase 1 (GOT1), glucose-6-phophatase (G6Pase), 
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phosphoenolpyruvate carboxykinase (PEPCK) and stearoyl-coenzyme A desaturase 1 
(SCD1) in males. 
After 4 h of fasting, males exhibited higher levels of hepatic glycogen content.  This 
sex-difference was maintained even after the reduction in hepatic glycogen content 
seen in the 12 h -fasted rats (Fig. 10), whereas there were no sex differences in hepatic 
triglyceride (TG) content, FA oxidation rate, and ketone bodies in blood.  
Interestingly, after 4h and 12 h fasting, when perfusing the liver in situ, HGO was 
higher in perfusates collected from male rats (P < 0.0001) (Fig. 10), which is consistent 
with our gene expression studies. Males exhibited a higher ratio of insulin to glucagon 
at both time points. Significant decreases in PG levels were observed after 12 h of 
fasting in both sexes. PG levels at different durations of fasting showed no sex 
differences at any time point. The inconsistency between glucose levels in plasma and 
liver perfusates might be explained by differences in glucose uptake by peripheral 
tissues.   
 
Analyses of liver perfusates, using 1H-NMR spectroscopy, revealed that perfusates 
from male rats contain significantly higher levels of glucose (P < 0.01), and also 
significantly higher levels of lactate (P < 0.01), and a trend to higher levels of glycerol 
and the gluconeogenic amino acids glutamine and glutamate. These findings are in line 
with our observation of  increased mRNA expression of key gluconeogenic enzymes, 
indicating that the male liver is more active in both producing and distributing glucose, 
and as well as generating metabolites important to glucose production. 
Fig. 10: Effects of fasting on hepatic glycogen content and glucose output in male and female rats. Data 
are represented as means ± SEM, and (*) indicates a significant difference compared to the corresponding 
male group, whereas (#) indicates a significant difference compared to the corresponding 4h fasting 
group. 
 
 
The reduction in glucose output after 40 min of insulin injection was greater in male 
rats, whereas the extent of the insulin suppressive effect on HGO was similar in male 
and female when expressed as a percentage of the basal glucose level. This indicates 
that male and female rat livers were equally sensitive to insulin, and that the sex-
difference in HGO was maintained upon insulin treatment. In addition, the effects of 
insulin on PG levels were the same in males and females. Moreover, no sex differences 
were observed at the level of insulin receptor signaling with regards to Akt-
phosphorylation (Ser473) 40 min after insulin treatment. AMPK was Thr172-
phosphorylated to a lower degree in male livers, indicative of a higher activity through 
gluconeogenic pathways as compared to female livers. 
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In conclusion, the results of this study demonstrate higher ratios of insulin to glucagon 
levels, higher levels of hepatic glycogen, a lower degree of hepatic AMPK 
phosphorylation, higher expression levels of hepatic gluconeogenic genes and greater 
hepatic glucose output in healthy male rats, as compared to female rats. It is evident 
that fuel metabolism differs between male and female animals, as well as between men 
and women (Tarnopolsky and Ruby, 2001, Tarnopolsky, 2000, Devries et al., 2006). 
Differences between males and females in both body composition and hepatic 
metabolism may lead to differences in the onset of related diseases of metabolic 
imbalance. Moreover, diagnoses of these diseases by metabolic profiling may be 
confounded by sex-specific differences in such profiles.  
Also, we speculate that since males have higher rates of FA oxidation and glucose 
production, this may explain the increased risk for development of T2D in this sex.  
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5 THESIS SUMMARY  
The major goal of this thesis being to investigate the effects of factors on glucose 
homeostasis in health and T2D, and to characterize metabolic sex-differences in the 
liver, the following conclusions can be made from our results: 
 
Paper I- The study confirms that an extract of Gynostemma pentaphyllum (GP) exerts 
direct antihyperglycemic effects, as reflected by improving PG levels mainly through 
reducing hepatic glucose output, indicating improvements in hepatic insulin sensitivity. 
 
Paper II- The study provides evidence that shikonin increases glucose uptake in 
skeletal muscle. This effect may be mediated by an insulin-independent pathway 
involving increased intracellular calcium levels and GLUT4-translocation in skeletal 
muscle. 
 
Paper III- The study verifies that the non-hematopoietic erythropoietin analogue, 
ARA290, improved PG levels by increasing insulin release. Increases in intracellular 
calcium leading to exocytosis of insulin were detected as being involved in the 
potential mechanism underlying the increased insulin levels. It can be speculated that 
ARA290 possesses properties that make it of great interest for the development of 
novel treatments of T2D. 
 
Paper IV- The study provides evidence of sex-differences at the level of hepatic 
carbohydrate metabolism, suggesting an increased ability in the male liver than the 
female liver to respond to increased energy demands. 
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